Literature DB >> 20587416

Human beta1-adrenergic receptor is subject to constitutive and regulated N-terminal cleavage.

Anna E Hakalahti1, Miia M Vierimaa, Minna K Lilja, Esa-Pekka Kumpula, Jussi T Tuusa, Ulla E Petäjä-Repo.   

Abstract

The beta(1)-adrenergic receptor (beta(1)AR) is the predominant betaAR in the heart, mediating the catecholamine-stimulated increase in cardiac rate and force of contraction. Regulation of this important G protein-coupled receptor is nevertheless poorly understood. We describe here the biosynthetic profile of the human beta(1)AR and reveal novel features relevant to its regulation using an inducible heterologous expression system in HEK293(i) cells. Metabolic pulse-chase labeling and cell surface biotinylation assays showed that the synthesized receptors are efficiently and rapidly transported to the cell surface. The N terminus of the mature receptor is extensively modified by sialylated mucin-type O-glycosylation in addition to one N-glycan attached to Asn(15). Furthermore, the N terminus was found to be subject to limited proteolysis, resulting in two membrane-bound C-terminal fragments. N-terminal sequencing of the fragments identified two cleavage sites between Arg(31) and Leu(32) and Pro(52) and Leu(53), which were confirmed by cleavage site and truncation mutants. Metalloproteinase inhibitors were able to inhibit the cleavage, suggesting that it is mediated by a matrix metalloproteinase or a disintegrin and metalloproteinase (ADAM) family member. Most importantly, the N-terminal cleavage was found to occur not only in vitro but also in vivo. Receptor activation mediated by the betaAR agonist isoproterenol enhanced the cleavage in a concentration- and time-dependent manner, and it was also enhanced by direct stimulation of protein kinase C and adenylyl cyclase. Mutation of the Arg(31)-Leu(32) cleavage site stabilized the mature receptor. We hypothesize that the N-terminal cleavage represents a novel regulatory mechanism of cell surface beta(1)ARs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587416      PMCID: PMC2937912          DOI: 10.1074/jbc.M110.149989

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  A monoclonal thyroid-stimulating antibody.

Authors:  Takao Ando; Rauf Latif; Alla Pritsker; Thomas Moran; Yuji Nagayama; Terry F Davies
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process.

Authors:  Evelina Grantcharova; Jens Furkert; H Peter Reusch; Hans-Willi Krell; Gisela Papsdorf; Michael Beyermann; Ralf Schulein; Walter Rosenthal; Alexander Oksche
Journal:  J Biol Chem       Date:  2002-09-10       Impact factor: 5.157

3.  Differences in endosomal targeting of human (beta)1- and (beta)2-adrenergic receptors following clathrin-mediated endocytosis.

Authors:  Wei Liang; Patricia K Curran; Quang Hoang; R Travis Moreland; Peter H Fishman
Journal:  J Cell Sci       Date:  2004-01-20       Impact factor: 5.285

4.  Resistance of the human beta 1-adrenergic receptor to agonist-mediated down-regulation. Role of the C terminus in determining beta-subtype degradation.

Authors:  Wei Liang; Steven Austin; Quang Hoang; Peter H Fishman
Journal:  J Biol Chem       Date:  2003-07-29       Impact factor: 5.157

5.  N-glycan-mediated quality control in the endoplasmic reticulum is required for the expression of correctly folded delta-opioid receptors at the cell surface.

Authors:  Piia M H Markkanen; Ulla E Petäjä-Repo
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

6.  Structure of a beta1-adrenergic G-protein-coupled receptor.

Authors:  Tony Warne; Maria J Serrano-Vega; Jillian G Baker; Rouslan Moukhametzianov; Patricia C Edwards; Richard Henderson; Andrew G W Leslie; Christopher G Tate; Gebhard F X Schertler
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

7.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

8.  Phe27Cys polymorphism alters the maturation and subcellular localization of the human delta opioid receptor.

Authors:  Tarja T Leskelä; Piia M H Markkanen; Ilkka A Alahuhta; Jussi T Tuusa; Ulla E Petäjä-Repo
Journal:  Traffic       Date:  2008-10-29       Impact factor: 6.215

9.  Regulated shedding of PAR1 N-terminal exodomain from endothelial cells.

Authors:  Matthew J Ludeman; Yao Wu Zheng; Kenji Ishii; Shaun R Coughlin
Journal:  J Biol Chem       Date:  2004-02-24       Impact factor: 5.157

10.  Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor.

Authors:  Michael P Bokoch; Yaozhong Zou; Søren G F Rasmussen; Corey W Liu; Rie Nygaard; Daniel M Rosenbaum; Juan José Fung; Hee-Jung Choi; Foon Sun Thian; Tong Sun Kobilka; Joseph D Puglisi; William I Weis; Leonardo Pardo; R Scott Prosser; Luciano Mueller; Brian K Kobilka
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

View more
  15 in total

Review 1.  The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases.

Authors:  A Rietz; Jp Spiers
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  G Protein-Coupled Receptors in the Sweet Spot: Glycosylation and other Post-translational Modifications.

Authors:  Christoffer K Goth; Ulla E Petäjä-Repo; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-17

3.  Site-specific O-Glycosylation by Polypeptide N-Acetylgalactosaminyltransferase 2 (GalNAc-transferase T2) Co-regulates β1-Adrenergic Receptor N-terminal Cleavage.

Authors:  Christoffer K Goth; Hanna E Tuhkanen; Hamayun Khan; Jarkko J Lackman; Shengjun Wang; Yoshiki Narimatsu; Lasse H Hansen; Christopher M Overall; Henrik Clausen; Katrine T Schjoldager; Ulla E Petäjä-Repo
Journal:  J Biol Chem       Date:  2017-02-06       Impact factor: 5.157

4.  Differential regulation of two palmitoylation sites in the cytoplasmic tail of the beta1-adrenergic receptor.

Authors:  David M Zuckerman; Stuart W Hicks; Guillaume Charron; Howard C Hang; Carolyn E Machamer
Journal:  J Biol Chem       Date:  2011-04-04       Impact factor: 5.157

5.  N-Tertaining a New Signaling Paradigm for the Cardiomyocyte β 1 -Adrenergic Receptor.

Authors:  Susan F Steinberg
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

6.  A sensor of protein O-glycosylation based on sequential processing in the Golgi apparatus.

Authors:  Collin Bachert; Adam D Linstedt
Journal:  Traffic       Date:  2012-10-31       Impact factor: 6.215

7.  Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus.

Authors:  Ieva Bagdonaite; Rickard Nordén; Hiren J Joshi; Sarah L King; Sergey Y Vakhrushev; Sigvard Olofsson; Hans H Wandall
Journal:  J Biol Chem       Date:  2016-04-15       Impact factor: 5.157

8.  A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation.

Authors:  Christoffer K Goth; Adnan Halim; Sumeet A Khetarpal; Daniel J Rader; Henrik Clausen; Katrine T-B G Schjoldager
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

9.  Endogenous N-terminal Domain Cleavage Modulates α1D-Adrenergic Receptor Pharmacodynamics.

Authors:  Timothy S Kountz; Kyung-Soon Lee; Stacey Aggarwal-Howarth; Elizabeth Curran; Ji-Min Park; Dorathy-Ann Harris; Aaron Stewart; Joseph Hendrickson; Nathan D Camp; Alejandro Wolf-Yadlin; Edith H Wang; John D Scott; Chris Hague
Journal:  J Biol Chem       Date:  2016-07-05       Impact factor: 5.157

10.  β1-adrenergic receptor N-terminal cleavage by ADAM17; the mechanism for redox-dependent downregulation of cardiomyocyte β1-adrenergic receptors.

Authors:  Jing Zhu; Susan F Steinberg
Journal:  J Mol Cell Cardiol       Date:  2021-02-06       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.